People · Operator
Named in public records as an officer, director or promoter · active 2009–2012 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aastrom Biosciences Inc | — | Biotechnology | Series C | $40.0M | $1.6B | 2012 |
| QUATRX PHARMACEUTICALS Co | — | Pharmaceuticals | Series A | $14.0M | $434.4M | 2009 |
Robert L. Zerbe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert L. Zerbe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 1 | 11 |
| Chris Ehrlich | 1 | 6 |
| Timothy M. Mayleben | 1 | 4 |
| Anders Hove | 1 | 4 |
| Nick Simon | 1 | 3 |
| Alan L. Rubino | 1 | 3 |
| Christopher Nicholas | 1 | 2 |
| Rick Fox | 1 | 2 |
| Nelson M. Sims | 1 | 2 |
| Ronald M. Cresswell | 1 | 2 |
| Brian D. Gibson | 1 | 1 |
| Harold C. Urschel | 1 | 1 |
| Stuart Dombey | 1 | 1 |
| Chris Moller | 1 | 1 |
| Gary Onn | 1 | 1 |
| Jeffery M Brinza | 1 | 1 |
| Anders Wiklund | 1 | 1 |
| August Watanabe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.